Drug factory · FDA FEI 3002806664
Laxai Life Sciences Private Limited
Plot No. 9/A, Phase-III, Jeedimetla, Quthubullapur, , Medchal-Malkajgiri District, India
No problems found at FDA's last inspection, Mar 14, 2025.
No Action Indicated: inspectors found no objectionable conditions.
4 drug inspections on record since 2012: 2 with no problems, 2 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Naproxen and Sumatriptan | Makes the active ingredient | Currax Pharmaceuticals LLC dba Cypress, Hawthorn, Macoven | 42847-850, 44183-850 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Mar 14, 2025 | No problems found | Drug Quality Assurance | — |
| Aug 3, 2019 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Apr 24, 2015 | No problems found | Drug Quality Assurance | — |
| Apr 16, 2012 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
Registered with FDA for: analysis; api manufacture.